These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31890985)

  • 1. Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials.
    Dombeck CB; Hinkley T; Fordyce CB; Blanchard K; Roe MT; Corneli A
    Contemp Clin Trials Commun; 2020 Mar; 17():100502. PubMed ID: 31890985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One and done: Reasons principal investigators conduct only one FDA-regulated drug trial.
    Corneli A; Pierre C; Hinkley T; Lin L; Fordyce CB; Hamre G; Roe MT
    Contemp Clin Trials Commun; 2017 Jun; 6():31-38. PubMed ID: 29740635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigator Experiences Using Mobile Technologies in Clinical Research: Qualitative Descriptive Study.
    McKenna KC; Geoghegan C; Swezey T; Perry B; Wood WA; Nido V; Morin SL; Grabert BK; Hallinan ZP; Corneli AL
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e19242. PubMed ID: 33576742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving and sustaining the site investigator community: Recommendations from the Clinical Trials Transformation Initiative.
    Fordyce CB; Malone K; Forrest A; Hinkley T; Corneli A; Topping J; Roe MT
    Contemp Clin Trials Commun; 2019 Dec; 16():100462. PubMed ID: 31701037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Engagement Partnerships in Clinical Trials: Development of Patient Partner and Investigator Decision Aids.
    Parry M; Bjørnnes AK; Toupin-April K; Najam A; Wells D; Sivakumar A; Richards DP; Ceroni T; Park M; Ellis AK; Gilron I; Marlin S
    Patient; 2020 Dec; 13(6):745-756. PubMed ID: 33026639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in clinical trial investigator workforce and turnover: An analysis of the U.S. FDA 1572 BMIS database.
    Fordyce CB; Roe MT; Pierre C; Hinkley T; Hamre G; Tenaerts P; McCall J; Topping JD
    Contemp Clin Trials Commun; 2019 Sep; 15():100380. PubMed ID: 31193608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EXPLORING REASONS THAT U.S. MD-PHD STUDENTS ENTER AND LEAVE THEIR DUAL-DEGREE PROGRAMS.
    Chakraverty D; Jeffe DB; Dabney KP; Tai RH
    Int J Dr Stud; 2020; 15():461-483. PubMed ID: 33815015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of patient engagement on trials and trialists in Ontario, Canada: An interview study with IMPACT awardees.
    Nicholls SG; Fox G; Monfaredi Z; Poole E; Garritty C; Maybee A; Presseau J; Shea B; Fergusson DA
    Res Involv Engagem; 2022 Sep; 8(1):50. PubMed ID: 36071496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the investigators: a qualitative study investigating the barriers and enablers to the implementation of local investigator-initiated clinical trials in Ethiopia.
    Franzen SR; Chandler C; Enquselassie F; Siribaddana S; Atashili J; Angus B; Lang T
    BMJ Open; 2013 Nov; 3(11):e003616. PubMed ID: 24285629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigator barriers and preferences to conduct clinical drug trials in Finland: a qualitative study.
    Keinonen T; Keränen T; Klaukka T; Saano V; Ylitalo P; Enlund H
    Pharm World Sci; 2003 Dec; 25(6):251-9. PubMed ID: 14689812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Are the Trends in Women's Representation Among Lead Investigators of Orthopaedic Clinical Trials?
    Burkhart RJ; Karimi AH; Hecht CJ; Avila A; Acuña AJ; Kamath AF
    Clin Orthop Relat Res; 2024 Jan; 482(1):35-44. PubMed ID: 37493365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Legal and ethical obligations to conduct a clinical drug trial in Australia as an investigator initiated and sponsored study for an overseas pharmaceutical company.
    Beran RG
    Med Law; 2004; 23(4):913-24. PubMed ID: 15685926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The profile of the one-time 1572 investigator.
    Glass HE
    Contemp Clin Trials; 2009 Jan; 30(1):34-9. PubMed ID: 18835461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada.
    Briel M; Elger BS; McLennan S; Schandelmaier S; von Elm E; Satalkar P
    Trials; 2021 Nov; 22(1):844. PubMed ID: 34823582
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.